Information
GEXVal CEO Selected as Invited Speaker at CPHI Japan 2026
2026/4/15
GEXVal Inc.April 15, 2026 GEXVal CEO Selected as Invited Speaker at Drug Discovery Symposium of CPHI Japan 202 […]
Announcement of Appointment of External Director
2026/3/25
GEXVal Inc.March 25, 2026 Unlocking the Value of Drug Discovery Through IP Strategy — Appointment of of Dr. Ka […]
GEXVal CTO to Present at the Annual Meeting of the PSJ
2026/3/25
GEXVal Inc.March 25, 2026 GEXVal CTO to Present at the 146th Annual Meeting of the Pharmaceutical Society of J […]
CTO Nakayama Contributes Invited Article to Experimental Medicine, Japan’s Leading Life Science Journal, on AI-Driven Drug Discovery
2026/3/12
GEXVal Inc.March 12, 2026 CTO Nakayama Contributes Invited Article to Experimental Medicine Special Issue on A […]
Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation
2026/2/28
GEXVal Inc.February 28, 2026 FRAXA Research Foundation Features GEXVal's Completion of FRAXA-DVI Program and F […]